## Abstract ## Objective Patients with systemic lupus erythematosus (SLE) are significantly more likely to experience a myocardial infarction or a stroke than age‐matched controls. We compared the prevalence of conventional and lupus‐specific risk factors in patients with SLE just before a cardiov
Factors determining participation in prevention trials among systemic lupus erythematosus patients: a qualitative study
✍ Scribed by Costenbader, Karen H. ;Brome, Deborah ;Blanch, Danielle ;Gall, Victoria ;Karlson, Elizabeth ;Liang, Matthew H.
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 77 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Objective
A feasibility study for a trial of strategies for the prevention of atherosclerosis in patients with systemic lupus erythematosus (SLE) was stopped because of inadequate recruitment. There is little understanding of the factors influencing patients' decisions about participation in prevention trials. Our goal was to determine factors that patients with SLE consider in deciding about participating in prevention trials, to uncover concerns about SLE trials, and to investigate how study design and purpose affect participation decisions.
Methods
We conducted focus groups with trial participants (n = 13), trial nonparticipants (n = 8), and a group of patients with diabetes (n = 9). We conducted telephone interviews with SLE patients who refused participation in the trial and the focus groups (n = 10). A trained facilitator elicited factors influencing participation decisions. Transcripts were coded and grouped into themes using grounded theory.
Results
Demographic characteristics of the groups were similar. Seven factors emerged as important in decision making: current health status, study design, physician involvement, personal benefit, altruism, time, and incentives. These factors were considered by individuals who elected to participate and those who did not, but weighed differently. Among the trial participants, good health status, encouragement from one's physician, and desires to learn and to contribute stimulated participation. Reasons for nonparticipation included current health status, medication and randomization concerns, and personal factors.
Conclusion
We observed that similar factors were weighed differently by participants and nonparticipants. Our results suggest that strategies such as health education, enlistment of personal physicians, and limitation of time requirements may enhance recruitment of patients with SLE into clinical prevention trials.
📜 SIMILAR VOLUMES
## Abstract ## Objective To determine whether LJP 394 delays or prevents renal flare in patients with systemic lupus erythematosus (SLE) and a history of renal disease. ## Methods In a 76‐week, double‐blind, placebo‐controlled study, 230 SLE patients were randomized to receive 16 weekly doses of
## Abstract ## Objective To clarify whether age at the time of the initial administration of corticosteroids is a risk factor for corticosteroid‐associated osteonecrosis in children with systemic lupus erythematosus (SLE), using magnetic resonance imaging (MRI). ## Methods From 1986 to 2007, MRI
## Abstract ## Objective Venous thrombosis is a relatively frequent and serious complication in systemic lupus erythematosus (SLE) that has been associated with the presence of antiphospholipid antibodies (aPL). However, venous thrombotic events can also be seen in patients without aPL, and only a
## Abstract ## Objective Serial measurements of anti–double‐stranded DNA (anti‐dsDNA) and complement are routine in the management of systemic lupus erythematosus (SLE), but their utility as biomarkers in preemptive treatment to prevent flares remains a subject of controversy. We hypothesized that